Background-Equations to estimate glomerular filtration rate (GFR) are routinely used to assess kidney function. Current equations have limited precision and systematically underestimate measured GFR at higher levels.
Introduction
Clinical assessment of kidney function is part of routine medical practice for adults, essential for assessing overall health, interpreting signs and symptoms, dosing drugs that are excreted by the kidneys, preparing for invasive diagnostic or therapeutic procedures, and detecting, evaluating and monitoring acute and chronic kidney diseases. The glomerular filtration rate (GFR) is considered the best overall index of kidney function in health and disease. GFR cannot be measured easily in clinical practice. Instead, GFR is estimated from equations using serum creatinine, age, race, sex and body size (1, 2) . One such equation, the Modification of Diet in Renal Disease (MDRD) Study equation, has gained widespread acceptance (3, 4) , and estimated GFR using this equation is reported by most clinical laboratories when measurement of serum creatinine is ordered (5) . The MDRD Study equation is also used to assess the burden of chronic kidney disease in epidemiologic studies and public health (6) The MDRD Study equation was developed in people with CKD, and as such its major limitations are imprecision and systematic underestimation of measured GFR (bias) at higher levels (8) . Our objectives were to develop and validate a new estimating equation based on serum creatinine that would be as accurate as the MDRD Study equation at GFR less than 60 ml/min/1.73 m 2 and more accurate at higher GFR. We report development and validation of a new equation and compare it to the MDRD Study equation for estimating measured GFR and US prevalence of chronic kidney disease.
Methods
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) is a research group established by the National Institutes of Diabetes, Digestive and Kidney Disease. The institutional review boards of all participating institutions approved the study.
Equation Development and Validation
Details about study selection and analytical methods are provided in the Appendix.
Data sources-CKD-EPI collaborators provided data from research studies and clinical populations (hereafter referred to as "studies"). Briefly, we identified studies from the Medline database and through investigators' and collaborators' contacts (Appendix Figure 1) . Key inclusion criteria were measurement of GFR using exogenous filtration markers and ability to calibrate serum creatinine assay. Studies for development and internal validation of equations were restricted to those using urinary clearance of iothalamate. Studies for external validation included iothalamate and other filtration markers. Ten studies (6 research studies and 4 clinical populations) with a total of 8,254 participants were divided randomly into separate datasets for development (n=5,504) and internal validation (n=2,750) (Appendix Table 1 ) (3, (9) (10) (11) (12) (13) (14) (15) . Sixteen other studies (6 research studies and 10 clinical populations) with a total of 3,896 participants were used for external validation (Appendix Table 2 ). (13, (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) Laboratory methods-For all studies, we recalibrated serum creatinine values to the standardized creatinine measurements using the Roche enzymatic method (Roche-Hitachi PModule instrument with Roche Creatininase Plus assay, Hoffman-La Roche, Ltd., Basel, Switzerland) at the Cleveland Clinic Research Laboratory (Cleveland, OH) as previously described (29, 30 where GFR is expressed as mL/min/1.73 m 2 of body surface area 41 and S cr is expressed in mg/ dL(4).
Analyses in the development dataset-We pre-specified a process for developing equations using transformations of continuous variables and inclusion of additional variables and interactions to develop a large number of candidate equations. We used least squares linear regression to relate measured GFR to serum creatinine and clinical characteristics available in all databases. Predictor variables included serum creatinine, age, race (black vs. white and other), and sex in all models, as in the MDRD Study equation, and additional variables [diabetes (yes/no), prior organ transplant (yes/no), and weight, as assigned by the individual studies] in some models. Regression models were fit to all patients in the pooled development dataset, without accounting for study in the models. GFR and serum creatinine were transformed to natural logarithms to reflect their multiplicative (inverse) relationship and to stabilize variance across the range of GFR.
Appropriate transformations of log serum creatinine and age were determined by first fitting non-parametric smoothing splines to characterize the shape of the relationship of these factors with mean log measured GFR and then creating piecewise linear splines to correspond to observed non-linearity (Appendix Table 3 ) (31) . Additional variables and pair-wise interactions between them were included if they were significant (p <0.01 for additional variables and <0.001 for interactions) and improved model performance [relative reduction in root mean square error (RMSE) by 2% or more] (Appendix Table 4 ).
Analyses in the internal validation dataset-We verified statistical significance of predictor variables and interactions for all models and relative ranking of performance among models. Development and internal validation datasets were combined to derive final coefficients for each model. (1) . Sensitivity and specificity and concordance between estimated and measured GFR between equations were compared using the McNemar test. Concordance of estimated GFR stages between equations was compared using the sign test.
Analyses were computed using R (Version 2, Free Software Foundation, Inc., Boston, MA) and SAS software (Version 9.1, Cary, NC).
Estimation of U.S. prevalence
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional, multistage, stratified, clustered probability samples of the civilian, non-institutionalized population of the U.S. GFR was not measured in NHANES. Serum creatinine was measured using a kinetic rate Jaffe method and re-calibrated to standardized creatinine measurements obtained in at the Cleveland Clinic Research Laboratory (Cleveland, OH) (33) . GFR was estimated using the MDRD Study and the newly developed CKD-EPI equation. Estimates that exceeded 200 mL/min/1.73 m 2 were truncated at that level. Methods for collection, analysis, and reporting for albuminuria have been described (7, 34) . Albuminuria was defined as albumin-to-creatinine ratio ≥30 mg/ g. Repeated measurements, obtained in a subset of 1,241 NHANES 1988-1994 participants approximately 2 weeks after the original examination were used to estimate the persistence of albuminuria (34) . NHANES does not have accurate diagnoses of causes of kidney disease. CKD was defined as persistent albuminuria or estimated GFR <60 ml/min/1.73 m 2 (1). CKD was classified according to estimated GFR stages as defined above. Distributions of estimated GFR, estimated GFR stages and prevalence of CKD were compared for both equations.
Analyses were performed incorporating the sampling weights to obtain unbiased estimates from the complex NHANES sampling design using Stata (Version 10.0, StataCorp, College Station, TX). Standard errors for all estimates were obtained using the Taylor series (linearization) method following NHANES recommended procedures and weights (35) (36) (37) . Confidence intervals for prevalence estimates for CKD stages incorporating persistence data on of albuminuria were made using bootstrap methods implemented in Stata. Prevalence estimates were applied to the 2000 U.S. Census to obtain estimates of the number of individuals with CKD in the U.S.
Role of the Sponsor
The study was funded by a cooperative agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which allows the NIDDK substantial involvement in the design of the study and in the collection, analysis, and interpretation of the data. The NIDDK was not required to approve publication of the finished manuscript.
Results

Selection of Studies and Clinical Characteristics
Clinical characteristics of the participants in each dataset are shown in Table 1 . In the development dataset, mean (standard deviation) measured GFR was 68 (40) mL/min/1.73 m 2 and ranged between 2 and 190 mL/min/1.73 m 2 . In the external validation dataset, mean measured GFR, sex, and proportion of diabetes was similar to the development and internal validation datasets, but there were differences in age, body size, and the proportion of ethnic and racial minorities, kidney donors and organ transplant recipients.
Description of CKD-EPI Creatinine Equation
Variables included in the CKD-EPI equation for estimating log GFR are log serum creatinine [modeled as a two-slope linear spline with sex-specific knots at 62 μmol/L (0.7 mg/dL) in women and 80 μmol/L (0.9 mg/dL) in men], sex, race and age on the natural scale, compared to log serum creatinine without a spline, sex, race and age on the log scale in the MDRD Study equation (Appendix Table 5 ). In the CKD-EPI equation, the spline for log serum creatinine allows for steeper and identical slopes of GFR vs. serum creatinine for men and women for creatinine levels above the knots and less steep and different slopes for men and women for creatinine levels below the knots, leading to higher estimated GFR at lower creatinine values. The slope above the knots is similar to the MDRD Study equation. In both equations, the coefficient for Blacks is greater than 1.0, leading to a higher estimated GFR for Blacks than Whites at all levels of serum creatinine, but lower than in the MDRD Study equation. In the CKD-EPI equation, the relationship between GFR and sex varies according to the level of serum creatinine. For example, the predicted female-to-male ratio for estimated GFR varies from 0.83 to 0.92 when serum creatinine is between 44 to 71 μmol/L (0.5 and 0.8 mg/dL), and is 0.75 when serum creatinine is ≥80 μmol/L (≥0.9 mg/dL), whereas it is constant for the MDRD Study equation at 0.74 at all values for serum creatinine. There is an inverse relationship between estimated GFR and age for both equations, but at older age, the age term on the natural scale in the CKD-EPI equation leads to lower estimated GFR for the same level of creatinine than does the log age term in the MDRD Study equation. In the external validation dataset, models with additional variables for diabetes, organ transplant, and weight, or interactions among variables did not lead to substantially improved performance compared to the simpler models. Table 2 shows the CKD-EPI equation in a form that could be implemented in clinical laboratories.
Comparison of Performance of MDRD Study and CKD-EPI Equations
Figure 1 and Table 3 shows the performance of both equations in the validation dataset.
(Appendix Table 6 
Comparison of estimated GFR and Prevalence of CKD in NHANES using MDRD Study and CKD-EPI Equations
The Table 7 ). Similar reclassification in distribution of estimated GFR was observed among patients with and without albuminuria (Appendix Table  8 ).
The CKD-EPI equation leads to a lower estimated prevalence (95% CI) of CKD compared to the MDRD Study equation [11.5 (10.6, 12.4) Table 9 ).
Discussion
We developed a new equation, the CKD-EPI equation, to estimate GFR in adults from serum creatinine using a large database pooled from 10 studies. Using data pooled from 16 additional studies, we validated the CKD-EPI equation and showed that it is more accurate than the widely-used MDRD Study equation. The CKD-EPI equation has lower bias, especially at estimated GFR greater than 60 mL/min/1.73 m 2 ; however, precision remains limited. The improved accuracy of the CKD-EPI equation overcomes some of the limitations of the MDRD Study equation and has important implications for public health and clinical practice.
Lower bias at higher estimated GFR reflects use of a spline term for serum creatinine. The spline accounts for a weaker relationship between creatinine and GFR at lower vs. higher creatinine levels, consistent with reports from studies comprised primarily of subjects with higher measured GFR, such as kidney donors and young people with Type 1 diabetes without microalbuminuria (10, 15, 38) . Like the MDRD Study equation, the CKD-EPI equation includes age, race and sex as surrogates for non-GFR determinants of serum creatinine. These variables are associated with muscle mass, the main determinant of creatinine generation (39) . Imprecision of GFR estimates suggests that age, race and sex do not account for all variation in non-GFR determinants of serum creatinine.
The CKD-EPI equation should lead to more accurate estimates of the distribution of estimated GFR and the burden of CKD in the US population. Median estimated GFR was 9.5 ml/min/ 1.73 m 2 higher, leading to a 1.6% lower prevalence estimate for CKD (11.5% compared to 13.1% using the MDRD Study equation). Concerns have been raised about the use of the MDRD Study equation because of the high prevalence estimates in the elderly, women and Whites, compared to the low incidence rates of treated kidney failure in these groups (7, 40, 41) . Using the CKD-EPI equation, the prevalence is reduced in women and Whites, but remains high in the elderly. Possible explanations for the remaining disparities between prevalence and incidence include competing risk from fatal cardiovascular disease in the elderly and faster progression of kidney disease in men and Blacks (42, 43) .
Greater accuracy of the CKD-EPI equation should improve clinical decision making in patients with decreased kidney function. In particular, lower bias should reduce the rate of false-positive diagnoses of CKD stage 3 (estimated GFR <60 ml/min/1.73 m 2 ) in patients without CKD (measured GFR above 60 ml/min/1.73 m 2 and absence of markers of kidney damage). Patients with CKD are at higher risk for a variety of complications (44) (45) (46) (47) (48) (49) (50) , and guidelines and recommendations call for reduction in dosage of drugs excreted by the kidney, avoidance of contrast media for imaging procedures, avoidance of phosphate-based enemas in preparation for colonoscopy, and lower targets for cardiovascular risk factors in patients with decreased GFR. Importantly, falsely low levels of estimated GFR could lead to insufficient drug dosing, withholding important diagnostic tests, and over-aggressive cardiovascular risk factor reduction in patients without CKD. The impact of more accurate estimates at higher levels of GFR on clinical decision making should be evaluated.
Strengths of this study include its design, with separate large databases for development and validation of the new equation, and a pre-specified rigorous statistical analytical plan for introduction and testing of all variables in the development dataset. The pooled development and validation databases include participants with diverse clinical characteristics, with and without kidney disease, and across a wide range of measured GFR, allowing more general applicability than the MDRD Study equation. Comparison of equations in a separate validation dataset overcomes limitations of differences among studies in patient characteristics and methods for measurement of GFR and serum creatinine.
There are weaknesses of this study. First, it is unlikely that a single equation will work equally well in all populations. Second, we have pooled studies of different populations to develop and validate the CKD-EPI equation. We performed extensive analyses to examine possible studyeffects, but cannot rule out that some of the findings may reflect the specific studies included in our database. Third, the study population with higher levels of GFR is not representative of the general population, and there were relatively few participants older than 70 years of age or racial minorities other than Black who are at increased risk for CKD. Fourth, we had incomplete data on diabetes type, immunosuppressive agents for transplantation, measures of muscle mass, and other clinical conditions and medications that might affect serum creatinine independently from GFR; however, the variables that we evaluated are the most readily available and easy to ascertain for widespread clinical application. Fifth, the CKD-EPI equation is more complex than the MDRD Study equation, but can readily be implemented into clinical laboratory information systems using the same input variables as required for use of the MDRD Study equation. Finally, the new equation does not overcome limitations of serum creatinine as an endogenous filtration marker. All creatinine-based equations should be used with caution in people with abnormally high or low levels of muscle mass. Nevertheless, serum creatinine is central for clinical assessment of kidney function at the present time, and GFR estimates based on serum creatinine will continue to be used in clinical practice for the foreseeable future.
Further research is necessary to improve GFR estimation. Imprecision in GFR estimates may be secondary to non-GFR determinants of creatinine. Measures of imprecision may also be inflated by measurement error in GFR. Research should be directed towards improving GFR measurement and evaluation of cystatin C and novel filtration markers for GFR estimation, either alone or in combination with serum creatinine (51) . Studies in representative populations are necessary, especially in the elderly and racial and ethnic minorities.
In summary, the CKD-EPI creatinine equation is more accurate than the MDRD Study equation across a wide variety of populations and clinical conditions. Bias is improved, especially at higher levels of estimated GFR, although precision remains suboptimal. Improved accuracy of the CKD-EPI equation could have important implications for public health and clinical practice. We suggest that the CKD-EPI equation could replace the MDRD Study equation for estimated GFR reporting for general clinical use.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding Source: National Institutes of Health UO1 DK 053869, UO1 DK 067651, and UO1 DK 35073
Sources of funding/support: This research was supported by the following grants: UO1 DK 053869, UO1 DK 067651, and UO1 DK 35073. CKD-EPI is funded as part of a cooperative agreement in which the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has substantial involvement in the design of the study and the collection, analysis, and interpretation of the data. The NIDDK was not required to approve publication of the finished manuscript. 694 (13) 336 (12) 608 (16) p<0.001 Transplant recipient, n (%)
241 (4) 119 (4) 1134 (29) p<0.001 Diabetes, n (%)
1581 (29) 825 (30) 1089 (28) p=0.173 Mean height (SD), cm 170 (10) 170 (10) 170 (10) † p=0.90 Mean weight (SD), kg 82 (20) 82 (20) 79 (18) p<0.001 Mean body mass index (SD), kg/m2
28 (6) 28 (6) 27 (6) 
Comparison of the CKD-EPI and MDRD Study Equations in Estimating GFR
